Peptide guide
Selank: what it is and what the research actually shows
A Russian-developed anxiolytic peptide sold by prescription in Russia. Never approved by FDA or EMA, and most of its clinical record is small, Russian, and hard to check from outside the country.
Byline: Mark Sommers, editor. Sources checked 08-26-2026. Every claim below links to its PubMed record or FDA page.
Quick facts
- What is in it
- One synthetic peptide, a chain of seven amino acids built as an analog of tuftsin, a small peptide that occurs naturally in the immune system.
One molecule, not a blend. Selank is a synthetic heptapeptide. Anything sold as selank mixed with another peptide is not what was used in the studies below.
- Studied for
- Russian trials measured anxiety symptoms in adults with generalized anxiety disorder and related phobic, hypochondriac and somatoform conditions, using standard psychiatric rating scales, and compared selank's tolerability against older anxiety drugs. Separate lab and animal work has chased two proposed mechanisms: blocking the enzymes that break down enkephalins, small peptides tied to pain and mood, and acting on GABA receptors, the same target as benzodiazepine anxiety drugs. One small brain imaging study looked at its effect on resting brain connectivity in healthy volunteers.
- Human evidence, part by part
- SelankLimited5 human studies found
- Approved by the FDA?
- Not approved by FDA or EMA. Selank is registered and sold as a prescription anxiolytic in Russia, but it has no approval, no filed application, and no registered clinical trial with United States or European regulators. See where it stands.
Benefits
- Evidence Produced anxiety reduction similar to an older anxiety drug in a 62-person comparator trial. PMID 18454096
- Evidence Reduced anxiety and improved quality of life versus a benzodiazepine, with effects outlasting treatment by a week. PMID 25176261
- Evidence Reduced a benzodiazepine's usual side effects, like memory and sedation problems, when added to it, in 70 people. PMID 26356395
- Evidence Changed amygdala-related brain connectivity differently than semax, in a 52-person placebo-controlled scan study. PMID 32342318
- Suggested Discussed as a calming anxiolytic and mild nootropic, though the mechanism rests mainly on lab and animal work.
- Suggested Promoted as a quieter alternative to stimulant nootropics, per online clinician commentary.
- Suggested Discussed for reducing cortisol overactivity, per online clinician commentary.
Evidence items link to the study behind them. Suggested items are claims in circulation, not results.
Reported side effects
- No published trial or case report gives a specific count of side effects or dropouts for selank alone.
- Produced no meaningful toxicity signal in a mouse embryonic stem cell screen. PMID 29063333
- Reduced, rather than added to, a benzodiazepine's side effects when combined with it, in a 70-person study. PMID 26356395
- A 2021 review flags this drug class for possible abuse risk, though its cited safety data concerns a related drug. PMID 34396551
Safety, before anything else
Selank is not an approved medicine in the United States or the European Union. It is registered and sold as a prescription drug in Russia, where nearly all of its clinical evidence comes from. FDA has not evaluated it, no approval application has ever been filed, and it does not appear on any FDA list of substances allowed for compounding. Here is what the published record actually shows, and how much of it cannot be independently checked from outside Russia.
Selank
- In a mouse embryonic stem cell model that tested several Russian peptide drugs for toxic effects on cell survival and neuronal differentiation, selank produced an insignificant effect, meaning no meaningful toxicity signal in that lab assay. This is a cell culture screen, not evidence about safety in a living animal or a person. PMID 29063333
- In the 2015 trial pairing selank with phenazepam, adding selank reduced the standard side effects of phenazepam itself, such as memory impairment, sedation and sexual problems, rather than adding new ones on top. The abstract gives no selank-specific adverse event count. PMID 26356395
- A 2021 pharmacology review flags selank as poorly studied and warns that GABA-acting drugs in this class can carry abuse and dependence risk, but the specific safety data it cites, including rising poison control center calls, is about the related drug phenibut, not selank. PMID 34396551
- No published trial or case report gives a specific count of side effects, dropouts, or serious adverse events for selank on its own. The Russian efficacy trials describe tolerability only in general terms in their English abstracts, with no numeric adverse event tables, and no independent poison control or adverse event registry data specific to selank could be found.
We do not publish amounts or schedules of our own, on any page. The clinician commentary lower on this page quotes amounts that named clinicians state on camera, labeled and linked to the source video. Those are their words, not our guidance. Why we draw that line.
How to read the grades
Each study gets a tag. Cells in a dish means it never touched a living animal. Animals means mice or rats, usually. Small human study means a handful of people with no comparison group. Human trial means people were randomly split into treated and untreated groups, which is the only kind that can show an effect is real. Review and Systematic review sum up other studies. The full rule is on How we check.
Selank
Selank is a synthetic seven amino acid peptide built as an analog of tuftsin, a small peptide fragment that occurs naturally in the immune system. In Russia it is sold by prescription as an anxiolytic, meant to reduce anxiety, and is also described as having a mild nootropic effect on memory and alertness. Two mechanisms have been proposed. One is that it blocks the enzymes that break down enkephalins, small peptides involved in pain and mood regulation, so more of the body's own enkephalins stay active for longer. The other is that it acts as a positive allosteric modulator at GABA receptors, the same receptor family targeted by benzodiazepine anxiety drugs, though it appears to work at a different site than those drugs. Both mechanisms rest mostly on lab assays and animal work. How either one connects to what patients report has not been independently confirmed.
Human evidence: Limited. 5 human studies found in our search.
What has been studied
| Who or what was studied | What was found, and the catch | Source |
|---|---|---|
| Small human study n = 62 people | In 62 patients with generalized anxiety disorder and neurasthenia, selank and the older drug medazepam produced a similar reduction in anxiety on standard psychiatric rating scales, and selank also showed antiasthenic and mild stimulant like effects. A blood marker of enkephalin activity moved along with the improvement in anxiety. Limit: This is a comparator trial against another drug, not against placebo. It was published only in a Russian language journal, so its randomization, blinding and dropout numbers cannot be checked from the English abstract alone, and it has never been replicated outside Russia. | Zozulia 2008 PMID 18454096 |
| Small human study n = 60 people | In 60 patients with phobic, anxiety and somatoform disorders, selank produced a clear anxiolytic effect that outlasted treatment by about a week and improved quality of life, compared with the benzodiazepine phenazepam. Limit: The English abstract gives no detail on randomization or blinding. The full paper is in a Russian journal not indexed in English on PubMed, so the comparator dosing, dropout rate and statistical methods cannot be independently checked. | Medvedev 2014 PMID 25176261 |
| Small human study n = 70 people | Adding selank to phenazepam in 40 patients with anxiety spectrum disorders reduced the usual side effects of phenazepam, such as memory and attention problems, sedation and sexual disturbances, compared with 30 patients on phenazepam alone, while keeping the anxiolytic benefit. Limit: This tests selank as an add-on to a benzodiazepine, not selank alone against placebo, so how much benefit comes from selank itself cannot be separated out. Group sizes are small and the full methods exist only in Russian. | Medvedev 2015 PMID 26356395 |
| Small human study | In patients with anxiety-asthenic disorders who took selank for two weeks, a marker of immune balance in the blood, the Th1 to Th2 cytokine ratio, shifted in a consistent direction, and selank changed IL-6 gene activity in blood cells taken from patients with depression but not in cells from healthy people. Limit: No participant count is given in the English abstract, there is no placebo comparison, and this paper was published in the same year and journal as the Zozulia generalized anxiety trial, so it may report on an overlapping or identical group of patients, which cannot be confirmed from the abstracts alone. The immune marker shifts were not tied to any anxiety symptom score. | Uchakina 2008 PMID 18577961 |
| Small human study n = 52 people | In 52 healthy volunteers given a single dose of selank, the related peptide semax, or placebo, resting state brain scans showed selank changed the connection strength between the amygdala, a region tied to anxiety, and part of the temporal cortex, in a pattern distinct from semax. Limit: Participants were healthy volunteers, not people with anxiety, so this says nothing about symptom relief. The outcome is a brain scan connectivity measurement, not a behavioral or clinical one, and it reflects a single dose rather than ongoing treatment. | Panikratova 2020 PMID 32342318 |
| Small human study | Blood from patients with generalized anxiety disorder showed a shorter enkephalin half life and lower enkephalin-degrading enzyme activity than blood from people without anxiety, and selank added to plasma in the lab blocked that same enzyme activity, offered as the proposed mechanism behind its anxiolytic effect. Limit: The anxiety related blood finding is a lab comparison across patient groups, not a treatment trial, and no participant count is given. The enzyme blocking result was shown in mixed blood samples in the lab, not in a person who had actually taken selank, so the mechanism is a hypothesis rather than something confirmed in treated patients. | Zozulya 2001 PMID 11550013 |
| Animals | In rats made dependent on morphine, a single injection of selank reduced signs of opioid withdrawal, including convulsions and posture problems, though it was somewhat less effective than diazepam at the dose tested. Limit: Animal data only, in a withdrawal model, not a study of selank in people with opioid dependence. No human data exists testing selank for opioid withdrawal. | Konstantinopolsky 2022 PMID 36322304 |
| Review | This English language pharmacology review groups selank with the related drug phenibut as a poorly studied Russian drug with a GABA receptor mechanism that is sold to United States consumers as a dietary supplement, despite no formal safety evaluation by any regulator. Limit: It is a review, not new data, and its selank section is short. It classifies selank mainly by mechanism alongside other sedative drugs rather than assessing selank's own evidence base in depth, and most of its safety concern, including rising poison control center calls, is specifically about phenibut, not selank. | Doyno 2021 PMID 34396551 |
| Review | This review lays out the leading receptor level theory behind selank's anxiety effect: in receptor binding assays selank behaves as a positive allosteric modulator of GABA receptors, in a manner that overlaps with but is not identical to how benzodiazepines like diazepam act. Limit: The evidence behind the review's own claim comes from receptor binding assays in the lab, not from animal behavior or human trials, and the proposed mechanism has not been confirmed by an independent laboratory. | Vyunova 2018 PMID 30255741 |
Safety signals in the studies
- In a mouse embryonic stem cell model that tested several Russian peptide drugs for toxic effects on cell survival and neuronal differentiation, selank produced an insignificant effect, meaning no meaningful toxicity signal in that lab assay. This is a cell culture screen, not evidence about safety in a living animal or a person. PMID 29063333
- In the 2015 trial pairing selank with phenazepam, adding selank reduced the standard side effects of phenazepam itself, such as memory impairment, sedation and sexual problems, rather than adding new ones on top. The abstract gives no selank-specific adverse event count. PMID 26356395
- A 2021 pharmacology review flags selank as poorly studied and warns that GABA-acting drugs in this class can carry abuse and dependence risk, but the specific safety data it cites, including rising poison control center calls, is about the related drug phenibut, not selank. PMID 34396551
- No published trial or case report gives a specific count of side effects, dropouts, or serious adverse events for selank on its own. The Russian efficacy trials describe tolerability only in general terms in their English abstracts, with no numeric adverse event tables, and no independent poison control or adverse event registry data specific to selank could be found.
Most cited author in this list: Medvedev, 2 of 9 sources. When a small number of groups produce most of the evidence, independent replication is thinner than the source count suggests.
Where it stands with regulators
- Drugs@FDA query, checked 08-26-2026, returned NOT_FOUND. No approved product and no filed application on record for selank. Source
- FDA list of bulk drug substances nominated for compounding under section 503A, content updated May 14, 2026, checked 08-26-2026. Selank does not appear in category 1, bulk substances under evaluation, category 2, substances that raise significant safety concerns, or category 3, substances nominated without adequate support. It has not been formally nominated at all. Source
- ClinicalTrials.gov search for selank, checked 08-26-2026, returned no registered trial of the peptide. Every result returned was an unrelated study that happened to share a keyword. Source
- Doyno and White, Journal of Clinical Pharmacology, 2021, checked 08-26-2026. Groups selank with phenibut as a poorly studied Russian drug with a GABA receptor mechanism that is sold to United States consumers as a dietary supplement, with no formal safety evaluation by any regulator. Source
What is missing
The trials behind selank's anxiolytic reputation are all Russian, published only in Russian language psychiatric journals, and their full methods are not accessible through PubMed's English abstracts, so randomization, blinding, and dropout numbers cannot be independently checked. Sample sizes run 60 to 70 patients per trial. No selank trial has ever been registered with ClinicalTrials.gov, and none has been independently replicated outside Russia or published in a Western peer reviewed psychiatry journal with full methodological transparency. Two of the 2008 papers share the same year and journal and may report on an overlapping patient group, which cannot be confirmed from the abstracts. There is no published human safety or adverse event count specific to selank on its own, and both proposed mechanisms, enkephalin protection and GABA receptor modulation, rest mainly on lab and animal work that has not been confirmed in treated patients.
Clinician commentary (YouTube)
This is commentary, not evidence. 4 clinicians with large audiences discuss this on camera. Each video below is summarized in our words and linked so you can watch the source yourself. Any amounts mentioned are what the named clinician says on camera, not PeptideGauge guidance. The graded studies above remain the record of what is known. How this layer works.
Dr. Alex Tatem
In “Truth About More Popular Peptides (What Works, What’s Overhyped) | Peptide Tier List pt.2”, Dr. Alex Tatem discusses Selank. What he says, in short:
- He describes this compound (the ASR transcript renders the name inconsistently as Sank, Selen, and Sang, but the description matches Selank) as designed to activate GABAergic pathways to promote a relaxed state and better rest and recovery.
- He says there is a decent amount of clinical data behind it in a research context, and stresses that it is not a sedative, not Ambien, and not a benzodiazepine.
- He says the effect is subtle rather than a light switch, but that it does a decently good job at what it's meant to do.
- He gives it a B tier rating.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.
In “Every Popular Peptide Ranked | GLP-1, Growth Hormone, HCG, NAD+, IGF-1, Peptide Tier List”, Dr. Alex Tatem discusses Selank. What he says, in short:
- He describes Selank as designed to activate GABAergic pathways to produce a relaxed state, and stresses it is not a sedative like Ambien or a benzodiazepine.
- He says there is a decent amount of clinical research behind it, but that its effects are subtle rather than an immediate light-switch change.
- He gives Selank a B tier ranking as a recovery and relaxation aid.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.
Dr. Ashley Froese
In “Real Doctor: If I Started Peptides Today, I'd Do THIS (The Ultimate Peptide Roadmap)”, Dr. Ashley Froese discusses Selank. What she says, in short:
- She mentions selank only briefly, grouping it among the advanced peptides for someone looking for a calming, anxiety reducing neuropeptide effect.
- She says a beginner like Joe should not start with advanced peptides like selank.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.
Dr. Craig Koniver
Dr. Craig Koniver does not run a channel of his own. Each video below is an interview published by the show that recorded it.
In “Dr. Craig Koniver - The Godfather of Peptides | SRS #330” on Shawn Ryan Show, Dr. Craig Koniver discusses Selank. What he says, in short:
- He describes selank as the cousin of semax and puts both in the nervous system category of peptides.
- He says selank taps into the GABA system, which he calls our calming system.
- He notes those are the same receptors that alcohol and benzodiazepines tap into.
- He says selank is very calming for some people, hedging that it does not do this for everyone.
- He says the semax and selank combination is like a natural Adderall and that his clinic makes it into a nasal spray so patients can redose through the day.
- He adds that he is not going to say it is perfect and that it is certainly not for everybody.
Sank taps into the GABA system, which is our calming system.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Performance Medicine: Adrenals, Circadian Rhythm, Peptides, NAD, Ketamine w/ Dr. Craig Koniver #303” on Luke Storey, Dr. Craig Koniver discusses Selank. What he says, in short:
- He calls selank one of the Russian peptides, grouped with semax, and says they help with cognition and help people recover after a stroke or traumatic brain injury.
- He says selank helps supply more GABA to the nervous system.
- He describes using it in addiction work, alongside NAD to help rewire the brain and ketamine to help shape new neuronal connections.
- He says that in his experience it can change how someone sees the world around them and how they see themselves.
- He says patients on that approach want to find more connection in more meaningful and affectionate ways, which he contrasts with simply telling someone to come off a substance and make behavioral change.
we use a peptide selank, which helps supply more GABA to their nervous system
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
2 more videos where Dr. Craig Koniver covers Selank
In “Is Peptide Therapy the Future of Medicine? | Dr. Craig Koniver” on The Ancient Health Podcast, Dr. Craig Koniver discusses Selank. What he says, in short:
- He describes selank as another Russian peptide and the chemical cousin of semax.
- He says selank taps into the GABA system.
- He says he uses it particularly for women who tend to be ruminating more in their thoughts, both for sleep and for the cognitive side that ties into it.
- He says that on selank you feel a little more calm, centered and grounded, sleep better and relax, which he says in turn helps cognitive function.
- He likes it as a nasal spray for a quick hit to the nervous system, with the tradeoff that nasal delivery does not last as long as an injection.
if you do selank you'll feel a little bit more calm centered and grounded helps you sleep better but also helps you relax
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Episode 95: Dr. Craig Koniver - Founder of Koniver Wellness, Performance Medicine Expert” on Habits & Hustle w/ Jennifer Cohen, Dr. Craig Koniver discusses Selank. What he says, in short:
- He describes selank as the chemical cousin of semax and spells it out on camera as sel, a and k.
- He says it taps into the GABA system in the nervous system, which he identifies as the inhibitory, calming neurotransmitter.
- He says it helps people relax and helps with anxiety and things like that.
- He says he pairs it with semax rather than using it alone, in the context of cognitive and mood support.
- He frames the pair as part of how his clinic breaks peptides down by lifestyle goal, including a combination aimed at the brain.
which taps into the gaba system in our nervous system which is the inhibitory neurotransmitter the calming one and that helps people relax helps with anxiety
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
Dr. Jones, DC
In “Doctor Explains the Semax & Selank Cognitive Peptide (Risks, Benefits & Who It’s For)”, Dr. Jones, DC discusses Selank. What he says, in short:
- He says selank comes from a different family than semax, built off a small messenger the immune and nervous systems already use.
- He says the literature frames selank as an anxiolytic that takes the edge off anxiety, and stresses that it does this by calming overreactive stress wiring rather than by sedating you.
- He describes the reported effect as calm rather than tired or checked out, with the background buzzing turned down so people can think straight under pressure.
- He gives his own use case, saying he relies on selank before public speaking more than any other peptide because it tells his body to settle while he stays sharp.
- He says selank pairs well with semax rather than competing with it, and that people often run semax in the morning for drive and save selank for the evening.
- He applies the same gap rule to selank, saying it only pays off when there is real fog or stress to work on, and it will do little for someone already dialed in.
- He warns that the research chemical market is full of underdosed or degraded product, so people spray weak or dead product and conclude the peptide does not work.
The literature frames Selank as an anxiolytic meaning that it takes the edge off anxiety.
It does that by calming down overreactive stress wiring, not by sedating you.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
In “Doctor Reveals The 10 Most POWERFUL Peptide Stacks (Science Backed Peptides)”, Dr. Jones, DC discusses Selank. What he says, in short:
- He puts selank alongside semax in what he calls the calm and focus stack, with selank supplying the calm half of the pairing.
- He says selank can kill anxiety without the sedation, so the combined result is cognitive performance with calm rather than feeling anxious and wired.
- He describes the mechanism loosely as modulating certain brain chemicals to reduce anxiety and promote calm without making a person feel tired or foggy the way he says traditional anxiety medications do.
- He says the nasal spray route is chosen deliberately because the target is the brain.
- He states dosing his doctors use as around 1 milligram per application up to three times a day, alternating nostrils, with a break after two to three months if run daily.
- He says some patients use it daily for cognitive demands while others use it situationally before high pressure situations, and that response varies with lifestyle and overall health.
Cmax gives you the laser focus and the mental performance, but Clink can kill anxiety without the sedation.
Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.
Common questions
Is selank approved by the FDA?
No. Selank has never been approved by FDA or EMA, and as of August 2026 no approval application had ever been filed with either regulator. A search of the FDA drug database returns no match, and selank does not appear on FDA's list of bulk substances nominated for compounding. It is registered and sold as a prescription anxiolytic in Russia, which is where nearly all of the human evidence comes from.
What is selank supposed to do?
In Russia it is prescribed as an anxiolytic, a drug meant to reduce anxiety, with a mild reported nootropic effect on memory and alertness. Two mechanisms have been proposed to explain this: it may block the breakdown of enkephalins, small peptides tied to pain and mood, and it appears to act on GABA receptors, the same receptor family targeted by benzodiazepine anxiety drugs. Neither mechanism has been confirmed outside lab and animal work.
How strong is the clinical evidence?
Thin and hard to verify from outside Russia. The handful of human trials found are all Russian, involve 60 to 70 patients each, and were published in Russian language psychiatric journals where the full methods, randomization and blinding cannot be checked from the English abstract on PubMed. None of these trials has been registered with ClinicalTrials.gov, replicated by an independent group, or published in a Western peer reviewed journal with full methodological transparency.
Can I legally buy selank in the United States?
It is sold online, usually labeled as a research chemical or dietary supplement, but it has not been evaluated by FDA for safety or effectiveness for any use, has no filed approval application, and does not appear on FDA's list of substances that can lawfully be compounded. A 2021 pharmacology review specifically calls out selank, alongside phenibut, as being sold to United States consumers despite no formal government safety evaluation.
Is selank the same thing as semax?
No, though they are often studied side by side and come out of the same Russian research tradition. Semax is a fragment of ACTH studied mainly as a nootropic, while selank is a tuftsin analog studied mainly as an anxiolytic. At least one brain imaging study tested both in the same healthy volunteers and found they changed brain connectivity in different patterns, so they should not be treated as interchangeable.
What are the side effects of selank?
There is no published trial or case report that gives a specific count of side effects, dropouts, or serious adverse events for selank on its own. One small lab study found no meaningful toxicity signal in a mouse cell model, and one Russian trial reported that combining selank with a benzodiazepine reduced that drug's usual side effects rather than adding new ones. Beyond that, the tolerability claims in the Russian trials are described only in general terms, with no numeric safety tables in the English abstracts.
Why can't the Russian trials just be read directly?
Their full texts are published in Russian language journals that are not translated or indexed in full on PubMed, so only the English abstract is available to check outside Russia. Abstracts of this length do not report randomization method, blinding, dropout counts, or full statistical results, which is exactly the information needed to judge how reliable a trial is. That gap, not the existence of the studies themselves, is the central problem with selank's evidence base.
Sources
- Doyno (2021). PMID 34396551
- Konstantinopolsky (2022). PMID 36322304
- Medvedev (2014). PMID 25176261
- Medvedev (2015). PMID 26356395
- Panikratova (2020). PMID 32342318
- Uchakina (2008). PMID 18577961
- Vyunova (2018). PMID 30255741
- Zozulia (2008). PMID 18454096
- Zozulya (2001). PMID 11550013
Selank has never been nominated for FDA's list of bulk drug substances usable in compounding, so it does not appear in any of that list's three categories, current as of May 14, 2026. Checked 08-26-2026.
Want these studies next to every other one on the site?
Open the evidence tableMixing a vial? Do the math with the calculator.
Open the calculator